An outbreak of synthetic cannabinoid exposures reported to a regional poison center: “K2” identified as 5F-ADB

Ann M. ArensMinnesota Poison Control System, Minneapolis, MN, USA; ;Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA; Correspondence[email protected]

Travis D. OlivesMinnesota Poison Control System, Minneapolis, MN, USA; ;Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA;

http://orcid.org/0000-0003-4330-1391

Nicholas S. SimpsonDepartment of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA;

JoaAn R. LaesMinnesota Poison Control System, Minneapolis, MN, USA; ;Division of Addiction Medicine, Hennepin Healthcare, Minneapolis, MN, USA;

Deborah L. AndersonMinnesota Poison Control System, Minneapolis, MN, USA;

Stacey A. BanghMinnesota Poison Control System, Minneapolis, MN, USA;

Samantha C. LeeMinnesota Poison Control System, Minneapolis, MN, USA;

Spencer MartinUniversity of California, San Francisco School of Medicine, San Francisco, CA, USA;

Samuel D. BanisterThe Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Camperdown, Australia;

Roy R. GeronaClinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, CA, USA

Jon B. ColeMinnesota Poison Control System, Minneapolis, MN, USA;

show all

References

Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology. 2018;134(Pt A):82–91.
PubMedGoogle Scholar
Adams AJ, Banister SD, Irizarry L, et al. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376:235–242.
PubMed Web of Science ®Google Scholar
Springer YP, Gerona R, Scheunemann E, et al. Increase in adverse reactions associated with use of synthetic cannabinoids—Anchorage, Alaska, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65:1108–1111.
PubMed Web of Science ®Google Scholar
Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370:389–390.
PubMed Web of Science ®Google Scholar
Cole JB, Klein LR, Nystrom PC, et al. A prospective study of ketamine as primary therapy for prehospital profound agitation. Am J Emerg Med. 2018;36:789–796.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

An outbreak of synthetic cannabinoid exposures reported to a regional poison center: “K2” identified as 5F-ADB

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An outbreak of synthetic cannabinoid exposures reported to a regional poison center: “K2” identified as 5F-ADB

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date